Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 4Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Breast Neoplasms, Male 1Bone Neoplasms 1Bone Diseases 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 17Docetaxel 13Specimen Handling 12Radiotherapy 11Surveys and Questionnaires 10Cyclophosphamide 10Blood Specimen Collection 9Radiosurgery 8Paclitaxel 8Gemcitabine 8Drug Therapy 8sargramostim 7Trastuzumab 7Nivolumab 7Carboplatin 7Injections 6Early Intervention, Educational 6Taxes 5Psychiatric Rehabilitation 5Methods 5Interviews as Topic 5Educational Status 5spartalizumab 4motexafin gadolinium 4aldesleukin 4X-Rays 4Therapeutics 4Standard of Care 4Spinal Puncture 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × saracatinib × Breast × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡